The treatment of juvenile myoclonic epilepsy

References

• Thomas P, Genton P, Gèlisse P, Wolf P. Juvenile myoclonic epilepsy. In: Epileptic syndromes in infancy, childhood and adolescences (4th Edition). Roger J, Bureau M, Dravet CH, Genton P, Tassinari CA, Wolf P (Eds). John Libbey Eurotext, Montrouge, France 367–388 (2005).
   Google Scholar
• Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia35, 285–296 (1994).
   PubMed Web of Science ®Google Scholar
• Obeid T, Panayiotopoulos CP. Juvenile myoclonic epilepsy: a study in Saudi Arabia. Epilepsia29, 280–282 (1988).
   Google Scholar
• Simonsen M, Mollgraard V, Lund M. A controlled clinical and electro-encephalographic study of myoclonic epilepsy. In: Epileptology. Janz D (Ed.), Thieme, Stuttgart, Germany 41–48 (1976).
   Google Scholar
• Gelisse P, Genton P, Rayband C, Thomas P, Dravet C. Structural brain lesions do not influence the prognosis of juvenile myoclonic epilepsy. Acta Neurol. Scand.102, 188–191 (2000).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ganesh S, Agarwala KL et al. A novel gene in the chromosomal region for juvenile myoclonic epilepsy on 6p12 encodes a brain-specific lysosomal membrane protein. Biochem. Biophys. Res. Commun.288, 626–636 (2001).
   Google Scholar
• Koepp MJ, Duncan JS. Epilepsy. Curr. Opin. Neurol.17, 467–474 (2004).
   Google Scholar
• Taylor I, Marini C, Johnson MR, Turner S, Berkovic SF, Scheffer IE. Juvenile myoclonic epilepsy and idiopathic photosensitive occipital lobe epilepsy: is there overlap? Brain127, 1878–1886 (2004).
   Google Scholar
• Janz D, Durner M. Juvenile myoclonic epilepsy. In: Epilepsy. A Comprehensive Textbook. Engel J, Pedley TA (Eds). Lippincott-Raven, PA, USA, 2389–2400 (1997).
   Google Scholar
• Jain S, Padma MV, Maheshwari MC. Occurrence of only myoclonic jerks in juvenile myoclonic epilepsy. Acta Neurol. Scand.95, 263–267 (1997).
   Google Scholar
• Genton P, Gelisse P, Thomas P. Juvenile myoclonic epilepsy today: current definitions and limits. In: Juvenile Myoclonic Epilepsy: The Janz Syndrome. Schmitz B, Sander T (Eds). Wrightson Biomedical Publishing, Petersfield, UK, 11–32 (2000).
   Google Scholar
• Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr. Drugs.3, 379–403 (2001).
   PubMedGoogle Scholar
• Panayiotopoulos CP, Obeid T, Waheed G. Absences in juvenile myoclonic epilepsy: a clinical and video-electroencephalographic study. Ann. Neurology25, 391–397 (1989).
   PubMed Web of Science ®Google Scholar
• Montalenti E, Imperiale D, Rovera A, Bergamasco B, Benna P. Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J. Neurol Sci.184, 65–70 (2001).
   PubMed Web of Science ®Google Scholar
• Gelisse P, Genton P, Thomas P, Rey M, Samuelian JC, Dravet C. Clinical factors of drugs resistance in juvenile myoclonic epilepsy. J. Neurol. Neurosurg. Psychiatry70, 240–243 (2001).
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Takahashi T, Sasaki M, Yoshida S, Numachi Y, Sato M. The long-term course of seizures susceptibility in two patients with juvenile myoclonic epilepsy. Seizure11, 126–130 (2002).
   PubMed Web of Science ®Google Scholar
• Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology34, 285–294 (1984).
   PubMed Web of Science ®Google Scholar
• Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia23, 693–720 (1982).
   PubMed Web of Science ®Google Scholar
• Dulac O, Steru D, Rey E et al. Sodium valproate monotherapy in childhood epilepsy. Brain Dev.8, 47–52 (1986).
   PubMed Web of Science ®Google Scholar
• Bourgeois B, Beaumanoir A, Blajev B et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia28(Suppl. 2), 8–11 (1987).
   PubMed Web of Science ®Google Scholar
• Penry JK, Dean JC, Riela AR. Juvenile myoclonic epilepsy: long-term response to therapy. Epilepsia30(Suppl. 4), 19–23 (1989).
   PubMed Web of Science ®Google Scholar
• Todt H, Muller D. The therapy of benign myoclonic epilepsy in infants. Epilepsy Res. (Suppl. 6), 137–139 (1992).
   Google Scholar
• Grunewald RA, Panayiotopoulos CP. Juvenile myoclonic epilepsy. A review. Arch. Neurol.50, 594–598 (1993).
   PubMedGoogle Scholar
• Bourgeois B. Valproic acid: clinical efficacy and use in epilepsy. In: Antiepileptic Drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott Williams & Wilkins, PA, USA, 812–813 (2002).
   Google Scholar
• Genton P, Gelisse P. Valproic acid: adverse effects. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott Williams & Wilkins, PA, USA, 837–847 (2002).
   Google Scholar
• Wyszynski DF, Holmes LB. The AED (antiepileptic drug) pregnancy registry: a six year experience. Epilepsia45(Suppl. 3), 56 (2004).
   Google Scholar
• Murphy K, Delanty N. Primary generalized epilepsy. Curr. Treat. Options Neurol.2, 527–542 (2000).
   Google Scholar
• Karlovassitou-Koniari A, Alexiou D, Angelopoulos P et al. Low dose sodium valproate in the treatment of juvenile myoclonic epilepsy. J. Neurol249, 396–399 (2002).
   Google Scholar
• De Toffol B, Autret A. Treatment of juvenile myoclonic epilepsy with low-dose sodium valproate. Rev. Neuro.152, 708–710 (1996).
   Google Scholar
• Calleja S, Salas-Puig J, Ribacoba R, Lahoz CH. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure10, 424–427 (2001).
   PubMed Web of Science ®Google Scholar
• Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine and topiramate and the prognosis of the idiopathic generalised epilepsies. J. Neurol. Neurosurg. Psychiatry75, 75–79 (2004).
   PubMed Web of Science ®Google Scholar
• Fernando-Dongas MC, Radtke RA, VanLandingham KE, Husain AM. Characteristics of valproic acid resistant juvenile myoclonic epilepsy. Seizure9, 385–388 (2000).
   PubMed Web of Science ®Google Scholar
• Obeid T, Panayiotopoulos CP. Clonazepam in juvenile myoclonic epilepsy. Epilepsia30, 603–606 (1989).
   PubMed Web of Science ®Google Scholar
• Schmidt D. Benzodiazepines: clinical efficacy and use in epilepsy. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott Williams & Wilkins, PA, USA, 207–208 (2002).
   Google Scholar
• Michelucci R, Tassinari CA. Benzodiazepines: adverse effects. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams & Wilkins, PA, USA, 215–221 (2002).
   Google Scholar
• Resor SR Jr, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology52, 1677–1681 (1990).
   Google Scholar
• Canevini MP, Mai R, Di Marco C, Bertin C, Minotti L, Pontrelli V. Juvenile myoclonic epilepsy of Janz: clinical observations in 60 patients. Seizure1, 291–298 (1992).
   PubMedGoogle Scholar
• Janz D, Durner M. Juvenile myoclonic epilepsy. In: Epilepsy: a comprehensive Textbook. Engel JJ, Pedley TA (Eds), Lippincott-Raven Publishers, PA, USA, 2389–2400 (1997).
   Google Scholar
• Covanis A, Katsalouli M. Levetiracetam monotherapy in generalised epilepsy and photosensitivity. Epilepsia44(Suppl. 8), 80 (2003).
   Google Scholar
• Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia46(Suppl. 9), 154–160 (2005).
   PubMedGoogle Scholar
• Biton V. Levetiracetam: adverse experiences. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott Williams & Wilkins, PA, USA, 442–447 (2002).
   Google Scholar
• Smith K, Betts T, Pritchett L. Levetiracetam, a promising option for the treatment of juvenile myoclonic epilepsy. Presented at the 4th European Congress on Epileptology, October 7, Firenze, Italy, (2000).
   Google Scholar
• Jongsma M, Janssen G, Engelsman M, Haan D. Promising results of levetiracetam in juvenile myoclonic epilepsy. Epilepsia43(Suppl. 8), 153 (2002).
   PubMed Web of Science ®Google Scholar
• Resor SR, Resor LD. Levetiracetam monotherapy in the treatment of convulsive seizures in juvenile myoclonic epilepsy. American Academy Neurology, 54th annual meeting (2002).
   Google Scholar
• Di Bonaventura C, Fattouch J, Mari F et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord.7, 231–235 (2005).
   PubMedGoogle Scholar
• Sharpe DV, Patel A, Fenichel GM, Abou-Khalil B. Use of levetiracetam in juvenile myoclonic epilepsy. Epilepsia46(Suppl. 8), 192 (2005).
   Google Scholar
• Andermann E, Andermann F, Meyvisch P, Schiemann Delgado J. Seizure control with levetiracetam in juvenile myoclonic epilepsies. Epilepsia46(Suppl. 8), 205 (2005).
   Google Scholar
• Khani YA, Andermann F, Andermann E. Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy. Epilepsia46, 1145–1146 (2005).
   Google Scholar
• Stephen LJ, Brodie MJ. Lamotrigine: clinical efficacy and use in epilepsy. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott Williams & Wilkins, PA, USA, 398 (2002).
   Google Scholar
• Pisani F, Richens A. Lamotrigine: adverse effects. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott Williams & Wilkins, PA, USA, 408–414 (2002).
   Google Scholar
• Guerrini R, Dravet C, Genton C, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia39, 508–512 (1998).
   PubMed Web of Science ®Google Scholar
• Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology55, 1758 (2000).
   PubMed Web of Science ®Google Scholar
• Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology56, 1424–1425 (2001).
   PubMed Web of Science ®Google Scholar
• Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr. Drugs3, 379–403 (2001).
   PubMedGoogle Scholar
• Prasad A, Kuzniecky RI, Knowlton RC et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch. Neurol.60, 1100–1105 (2003).
   Google Scholar
• Grunewald RA, Salas Puig J, Genton P, Panayiotopoulos CP. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch. Neurol.61, 1328 (2004).
   Google Scholar
• Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spams. Lancet344, 1375–1376 (1994).
   PubMed Web of Science ®Google Scholar
• Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia35, 359–367 (1994).
   PubMed Web of Science ®Google Scholar
• Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood.J. Pediatr.127, 991–997 (1995).
   PubMed Web of Science ®Google Scholar
• Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure5, 149–151 (1996).
   PubMed Web of Science ®Google Scholar
• Gerike CA, Picard F, Saint-Martin A, Strumia S, Marescaux C, Hirsch E. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled open study. Epileptic Disord.1, 159–165 (1999).
   Google Scholar
• Martinez JF, Fountain NB. Frequency of myoclonic seizure exacerbation by lamotrigine in JME. Epilepsia44(Suppl. 9), 268 (2003).
   Google Scholar
• Morris GL, Hammer AE, Kustra RP, Messenheimer JA. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav.5, 509–512 (2004).
   PubMedGoogle Scholar
• Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand.91, 200–202 (1995).
   PubMed Web of Science ®Google Scholar
• Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia40, 1141–1146 (1999).
   PubMed Web of Science ®Google Scholar
• Panayioutopoulos CP. Beneficial effect of relatively small doses of lamotrigine. Epilepsia40, 1171–1172 (1999).
   Google Scholar
• Barrera MN. Characteristics and indications of topiramate. Rev. Neurol.35, 88–95 (2002).
   Google Scholar
• Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand.107, 165–175 (2003).
   PubMed Web of Science ®Google Scholar
• Privitera MD, Twyman RE. Topiramate: clinical efficacy and use in epilepsy. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams & Wilkins, PA, USA, 749 (2002).
   Google Scholar
• Sachdeo RC, Karia RM. Topiramate: adverse effects. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams & Wilkins, PA, USA, 760–763 (2002).
   Google Scholar
• Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology52, 1330–1337 (1999).
   PubMed Web of Science ®Google Scholar
• Rosenfeld WE. Topiramate, a broad-spectrum agent, in patients with juvenile myoclonic epilepsy. Epilepsia40(Suppl. 2), 226 (1999).
   Google Scholar
• Prasad A, Kuzniecky R, Knowlton RC et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch. Neurol.60, 1100–1105 (2003).
   PubMedGoogle Scholar
• Levisohn PM, Holland KD, Hulihan JF, Fisher AC. Topiramate versus valproate in patients with juvenile myoclonic epilepsy. Epilepsia44(Suppl. 9), 267–268 (2003).
   Google Scholar
• Sousa Pda S, de Araujo Filho GM, Garzon E, Sakamoto AC, Yacubian EM. Topiramate for the treatment of juvenile myoclonic epilepsy. Arq. Neuropsiquiatr.63, 733–737 (2005).
   PubMed Web of Science ®Google Scholar
• Biton V, Bourgeois BF, YTC/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch. Neurol.62, 1705–1708 (2005).
   PubMedGoogle Scholar
• Seino M, Fujitani B. Zonisamide: clinical efficacy and use in epilepsy. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams & Wilkins, PA, USA, 890 (2002).
   Google Scholar
• Lee B. Zonisamide: adverse effects. In: Antiepileptic drugs, 5th Edition. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams & Wilkins, PA, USA, 892–897 (2002).
   Google Scholar
• Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord.6, 267–270 (2004).
   PubMed Web of Science ®Google Scholar
• Szaflarski JP. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav.5, 1024–1026 (2004).
   Google Scholar
• Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev.22, 75–78 (2000).
   PubMed Web of Science ®Google Scholar
• Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy ? Neurology55, 1106–1109 (2000).
   PubMed Web of Science ®Google Scholar
• Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy—reply. Arch. Neurology61, 1328–1329 (2004).
   Google Scholar
• Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxacarbamazepine in juvenile idiopathic generalized epilepsy. Epilepsia45, 1282–1286 (2004).
   PubMed Web of Science ®Google Scholar
• Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain129, 1281–1292 (2006).
   PubMed Web of Science ®Google Scholar